| Hazard Information | Back Directory | [Description]
Rifabutin-d7 is intended for use as an internal standard for the quantification of rifabutin by GC- or LC-MS. Rifabutin is a rifamycin antibiotic.1,2 It is active against a variety of Gram-positive and Gram-negative bacteria, including 81 clinical isolates of H. pylori (MIC50 = 0.25 μg/ml), as well as S. aureus, S. pyogenes, and C. trachomatis (MICs = 0.004, 0.005, and ~0.008 μg/ml, respectively). Rifabutin (0.5 μg/ml) is also active against 302 strains of M. tuberculosis.2 It inhibits protein synthesis via inhibition of DNA-dependent RNA polymerase (RNAP) activity.2 Rifabutin (10, 20, or 40 mg/kg) reduces the number of spleen, lung, and liver colony forming units (CFUs) in mouse models of disseminated Mycobacterium avium complex (MAC) infection.3 Formulations containing rifabutin have been used in the treatment of H. pylori infection. | [Uses]
Labelled Rifabutin (R505000). Semisynthetic derivative of Rifamycin S that inhibits nucleic acid synthesis. An antibacterial (tuberculostatic). | [References]
1. Heep, M., Beck, D., Bayerd?rffer, E., et al. Rifampin and rifabutin resistance mechanism in Helicobacter pylori Antimicrob. Agents Chemother. 43(6),1497-1499(1999).
2. Kunin, C.M. Antimicrobial activity of rifabutin Clin. Infect. Dis. 22(Supp. 1),S3-S14(1996).
3. Klemens, S.P., Grossi, M.A., and Cynamon, M.H. Comparative in vivo activities of rifabutin and rifapentine against Mycobacterium avium complex Antimicrob. Agents Chemother. 38(2),(1994). |
|
|